Patient Guide: A Study of LCAR-B38M CAR-T Cells, a Chimeric Antigen Receptor T-cell (CAR-T) Therapy Directed Against B-cell Maturation Antigen (BCMA) in Chinese Participants With Relapsed or Refractory Multiple Myeloma

Why Use Quri.ai for This Trial?

  • ✓ Simplified eligibility checker - know if you qualify in minutes
  • ✓ Direct contact with study coordinators at 11 locations
  • ✓ Plain language explanations of medical terms and procedures
  • ✓ Personalized enrollment support throughout your journey
  • ✓ Free service - no hidden fees or obligations
Trial ID: NCTNCT03758417
Status: ACTIVE_NOT_RECRUITING
Condition: Multiple Myeloma
Phase: PHASE2

Where You Can Participate

This study is available at 11 locations across the country.

Top locations include:
  • • Beijing, Beijing Municipality
  • • Fuzhou, Fujian
  • • Guandong, Guangzhou
  • • And 8 more locations

Loading interactive enrollment tools...

The full interactive experience will load momentarily

A Study of LCAR-B38M CAR-T Cells, a Chimeric Antigen Receptor T-cell (CAR-T) Therapy Directed Against B-cell Maturation Antigen (BCMA) in Chinese Participants With Relapsed or Refractory Multiple Myeloma - Join Clinical Trial NCTNCT03758417

How to Join This Clinical Trial - NCTNCT03758417

Learn how to participate in this PHASE2 trial studying an investigational therapy for Multiple Myeloma. Current status: ACTIVE_NOT_RECRUITING.

Am I Eligible for This Clinical Trial?

This clinical research study is looking for participants with Multiple Myeloma. Eligibility requirements include specific age ranges, health status, and medical history. Contact the study team to learn if you qualify.

Condition Being Studied
Multiple Myeloma
Treatment Being Tested
Investigational treatment
Study Phase
PHASE2 - Safety and effectiveness study
Enrollment Status
ACTIVE_NOT_RECRUITING
Study Identifier
NCTNCT03758417 - ClinicalTrials.gov Identifier
Sponsored By
Study sponsor

What to Expect as a Participant

Participating in this clinical trial involves:

  • Initial screening to determine eligibility
  • Regular study visits and health assessments
  • Receiving the study treatment or placebo
  • Medical monitoring and follow-up care
  • Contributing to medical research that may help others
  • Potential access to new treatments before they're widely available

Clinical Trial Benefits and Compensation

Participants in this clinical research study may receive:

  • Close medical monitoring by healthcare professionals
  • Access to potential new treatments
  • Compensation for time and travel (varies by study)
  • No-cost study-related medical care
  • The opportunity to help advance medical knowledge

Where Is This Clinical Trial Located?

This study is enrolling participants at 11 locations. Find a study site near you:

Clinical Research Site

Beijing, Beijing Municipality 100191 - China

Status: Contact for availability

Clinical Research Site

Fuzhou, Fujian 350001 - China

Status: Contact for availability

Clinical Research Site

Guandong, Guangzhou 510060 - China

Status: Contact for availability

Clinical Research Site

Nanjing, Jiangsu 210008 - China

Status: Contact for availability

Clinical Research Site

Nanjing, Jiangsu 210029 - China

Status: Contact for availability

Clinical Research Site

Shanghai, Shanghai Municipality 200003 - China

Status: Contact for availability

Clinical Research Site

Shanghai, Shanghai Municipality 200025 - China

Status: Contact for availability

Clinical Research Site

Shanghai, Shanghai Municipality 200434 - China

Status: Contact for availability

Clinical Research Site

Xi’an, Shanxi 710004 - China

Status: Contact for availability

Clinical Research Site

Chengdu, Sichuan 610041 - China

Status: Contact for availability

And 1 more locations available. Contact us to find the nearest participating site.

How to Enroll in This Study

To learn more about participating in this PHASE2 clinical trial for Multiple Myeloma:

  1. Review the eligibility criteria with your healthcare provider
  2. Contact the study team for a pre-screening interview
  3. Schedule an in-person screening visit if eligible
  4. Review and sign the informed consent form
  5. Begin participation in the clinical trial

Why Choose Quri.ai Study Finder

Quri.ai's Study Finder is the leading clinical trial business intelligence platform, helping BD professionals:

  • Discover clinical trials before competitors
  • Access exclusive contact information
  • Track sponsor pipelines and opportunities
  • Connect with decision makers directly
  • Win more business partnerships